Comments
Drug firm Torrent Pharma Inc is recalling over 8.82 lakh bottles of Losartan Potassium tablets, used for treatment of hypertension, from the US and Puerto Rico markets on account of deviations from the current good manufacturing norms, according to a report of the US health regulator.
The US-based arm of Torrent Pharmaceuticals is recalling 28,464 bottles of Losartan Potassium tablets USP in the strength of 25 mg manufactured by the parent company at its Indrad facility in Mehsana district, the latest Enforcement Report of the the United States Food and Drug Administration (USFDA) said.
All the ongoing voluntary recalls of the hypertension treatment drug are class II recalls, it added.
The reason for the recalls is “CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million”, the report said.
CGMP refers to the Current Good Manufacturing Practice regulations enforced by the USFDA.
As per the USFDA, a class II recall is initiated in a situation “in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote”.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.